1. Market Research
  2. > Pathology
Customer Support

Talk to Ahmad

+1 718 618 4302

Companies

  • All
    • Amgen Inc.
About 100 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • United States
  • Amgen Inc.

NHL: Mantle cell lymphoma

  • $ 5000
  • April 2016
  • 214 pages

Lymphoma Association (2016) Mantle cell lymphoma.

  • Immunotherapy
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.

Global Auto-Injectors Market (By Application/Indication, Product Type, Usability, Distribution Channels, Region), Key Company Profiles - Forecast to 2025

  • $ 1990
  • August 2019
  • 126 pages

lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD## therapies pursuant to its collaboration arrangements with Genentech, Inc.

  • Injectable Delivery
  • Lymphoma
  • World
  • Amgen Inc.
  • Antares Pharma, Inc.

Global Biologics Market: Size, Trends & Forecast (2019-2023 Edition)

  • $ 1200
  • December 2019
  • 97 pages

Enbrel ##. ## Rheumatoid arthritis Amgen, Pfizer Herceptin ##. ## Breast and gastric cancer Roche (Genentech) Avastin ##. ## Various cancers Roche (Genentech) Rituxin ##. ## Lymphoma, Rheumatoid arthritis Roche (Genentech), Biogen Eylea ##. ## Macular degeneration/ edema, retinopathy Bayer, Regeneron

  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical
  • World
  • Amgen Inc.

Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025

  • $ 3500
  • August 2020
  • 266 pages

IN MAY 2018, THE PRODUCT RECEIVED EXPANDED INDICATION APPROVAL FOR B-CELL LYMPHOMA.

  • Gene Therapy
  • Lymphoma
  • Therapy
  • World
  • Amgen Inc.

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • United States
  • Amgen Inc.

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 403 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Amgen Inc.

Global Regenerative Medicine Market - Opportunities and Forecast

  • $ 2400
  • August 2019
  • 326 pages

This strategic acquisition will further promote Gilead as an industry leader in refractory large B-cell lymphoma after two or more lines of therapy.

  • Biopharmaceutical
  • Lymphoma
  • Regenerative Medicine
  • Market Size
  • Amgen Inc.

Global Immuno-Oncology Market with Focus on Assays: Size, Trends and Forecasts (2019-2023)

  • $ 900
  • September 2019
  • 77 pages

On July ##, 2019, the US Food and Drug Administration (FDA) approved RUXIENCE, a biosimilar to Rituxan to treat the adult patients with lymphoma, leukemia and polyangiitis.

  • Lymphoma
  • Oncology
  • Therapy
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

Wearable Injectors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type ; Application ; End User ; and Geography

  • $ 4550
  • June 2020
  • 184 pages

The wearable injectors market was valued at US$ 5,791.23 million in 2019 and is projected to reach US$ 13,880.88 million by 2027; it is expected to grow at a CAGR of 11.6% during 2020-2027. Wearable injectors ...

  • Autoimmune Disease
  • Diabetes
  • Lymphoma
  • Forecast
  • Amgen Inc.

Global CML Market Report - 2022

  • $ 3849
  • June 2018
  • 82 pages

Imatinib mesylate is licensed as a firstline treatment for adults with chronic-phase Ph+ CML, and for the management of GIST, and as salvage therapy for Ph+ acute lymphoblastic lymphoma.

  • Lymphoma
  • Therapy
  • Amgen Inc.
  • Incyte Corporation
  • Merck & Co., Inc.

Colorectal Cancer Market to 2027- Global Analysis and Forecasts by Modality; End User, and Geography

  • $ 4550
  • November 2019
  • 229 pages

The largest impact is that it grows slowly, like solid tumors and leukemia, also used to treat lung, ovarian cancer, and breast cancer, as well as for lymphomas, sarcomas, myelomas.

  • Colorectal Cancer
  • Lymphoma
  • Forecast
  • Market Size
  • Amgen Inc.

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • January 2019
  • 201 pages

ALTHOUGH CELLTRION' S TRUXIMA WAS SIMILARLY TREATED BY THE FDA, THE COMPANY COMPLIED WITH REQUESTS FOR ADDITIONAL DATA AND IN NOVEMBER 2018, CELLTRION' S TRUXIMA WAS APPROVED, BUT ONLY FOR THE TREATMENT OF B-CELL NON-HODGKIN AND FOLLICULAR LYMPHOMAS (CELLTRION, PRESS RELEASE, ## NOV

  • Biosimilar
  • Hospital
  • Lymphoma
  • Therapy
  • Amgen Inc.

Global Regenerative Medicine Market 2018-2022

  • $ 2500
  • April 2018
  • 134 pages

Approximately ##% of clinical trials of regenerative medicine are being conducted in oncology indications such as leukemia, lymphoma, brain cancer, breast cancer, bladder cancer, cervix cancer, colon cancer, esophageal cancer, ovarian cancer, and pancreatic cancer.

  • Lymphoma
  • Regenerative Medicine
  • Amgen Inc.
  • MiMedx Group, Inc.
  • Organogenesis, Inc.

Global Biotechnology, MarketLine

  • $ 350
  • June 2018
  • 34 pages

lymphoma (FL), RA and certain types of ANCA-associated vasculitis, Actemra/ RoActemra, for rheumatoid arthritis, systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis, Xolair, for moderate to severe persistent allergic asthma and chronic idiopathic urtic

  • Biotechnology
  • Lymphoma
  • Amgen Inc.
  • Covance Inc.
  • F. Hoffmann-La Roche Ltd.

Myelodysplastic Syndromes: Opportunity Analysis and Forecasts to 2028

  • $ 10995
  • May 2020
  • 193 pages

GAMIDA HAS AN ONGOING PHASE III, MULTICENTER, RANDOMIZED, REGISTRATIONAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF TRANSPLANTATION WITH OMIDUBICEL VERSUS TRADITIONAL UCBT IN PATIENTS WITH LEUKEMIA, LYMPHOMA, AND KOLs noted that patients with TP##mutant MDS have exceptionally poor prognose

  • Blood Disease
  • Lymphoma
  • Therapy
  • United States
  • Amgen Inc.

Global Gene Therapy Market Report - 2026

  • $ 3849
  • July 2018
  • 105 pages

Lymphoma, B-Cell Lymphoma Cd##+ Diffuse Large B-Cell Lymphoma Undisclosed (Expected Oncology) Prostate Cancer, Lung Cancer Phase ## CTL## CAR-T Phase ##I BiTE platform CAR-T Phase ## LADD iMultiple Myelomauno-oncology platform Up to ## gene therapies including S##A## Phase ##

  • Gene Therapy
  • Lymphoma
  • Therapy
  • Amgen Inc.
  • Boehringer Ingelheim GmbH

Kidney Cancer Therapeutics & Diagnostics Market- Growth, Trends, and Forecasts (2020 – 2025)

  • $ 4250
  • July 2020
  • 135 pages

ADCETRIS is approved for some CD##-expressing lymphomas, while PADCEV is approved for certain metastatic urothelial cancers.

  • Diagnostics
  • Lymphoma
  • Renal Cancer
  • Therapy
  • Amgen Inc.

Biosimilars in Oncology

  • $ 7995
  • August 2018
  • 154 pages

SINCE ITS APPROVAL IN 1997, ROCHE' S RITUXAN HAS BEEN KEY IN THE NHL TREATMENT PARADIGM, AND FORMS THE BACKBONE OF CHEMOTHERAPY REGIMENS IN ALL THERAPY LINES FOR THE FOUR LARGEST B-CELL NHL INDICATIONS, DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), FOLLICULAR LYMPHOMA (FL), MARGINAL Z

  • Biosimilar
  • Lymphoma
  • Medical Biotechnology
  • Oncology
  • Amgen Inc.

Asia-Pacific Colorectal Cancer Market to 2027 - Regional Analysis and Forecasts by Modality ; End User, and Country

  • $ 3000
  • March 2020
  • 166 pages

The largest impact is that it grows slowly, like solid tumors and leukemia, also used to treat lung, ovarian cancer, and breast cancer, as well as for lymphomas, sarcomas, myelomas.

  • Colorectal Cancer
  • Lymphoma
  • APAC
  • Market Size
  • Amgen Inc.
View report >

Global Pharmaceutical Market

  • April 2018
  • 16 pages

Global Pharmaceuticals 2017 industry statistics During the last few weeks, most of the multi-national pharmaceutical companies have reported results for 2017, which has provided us with the opportunity to update our industry statistics and drug database.

  • Pharmaceutical
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company

Therapy Market in the US November 2019

Therapy Market January 2017

Therapy Market in the US September 2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on